This American customer had previously communicated with us, but it was quite a long time before they placed another order to purchase a box of tirzeptide 5mg. After the order was placed, the customer encountered a problem during the payment process: they tried multiple payment methods, but the system kept showing failure, preventing the order from entering the shipping process. The customer repeatedly checked their account information and communicated with the card issuer, conducting several payment operations. After much effort, finally, one payment was shown as successful. After receiving the confirmation, we immediately arranged for compliant shipping and updated the logistics tracking information for the customer.
Currently, the package has successfully arrived in the United States. The latest logistics status shows that it has completed customs clearance and is currently being processed at the local distribution center. It will soon enter the delivery stage. Although there were some setbacks from placing the order to successfully completing the payment, which led to an extended overall processing time, the order was eventually successfully completed. Customers will receive the product in the near future, and the communication and cooperation throughout the process remained largely smooth.
business process
Blood sugar control: Exceeding the hypoglycemic capabilities of a single target
The core efficacy of tirzepatide in the management of type 2 diabetes is primarily manifested in its potent reduction of glycated hemoglobin (HbA1c).
Significant reduction: In the SURPASS series of clinical trials, Tirzepatide can reduce HbA1c by up to 2.24%, which is a leading figure among similar drugs.
Head-to-head superior to GLP-1 receptor agonists: In a 40-week comparative trial, the three dose groups of Tirzepatide (5mg, 10mg, 15mg) were not inferior to and were superior to semaglutide 1.0mg in reducing HbA1c. The least squares mean estimated treatment differences were -1.9kg, -3.6kg, and -5.5kg (P<0.001).
An astonishing proportion of achieving normal blood glucose levels: In the highest dose group, approximately 50% of the subjects achieved a normal blood glucose level of HbA1c < 5.7%, which means that a significant portion of patients have seen substantial improvement in their β-cell function.
Glucose-dependent insulin secretion: Tirzepatide enhances insulin secretion by pancreatic β-cells in the first and second phases in a glucose-dependent manner, while inhibiting the secretion of glucagon by α-cells, thereby reducing glucose output from the liver. This mechanism makes its risk of hypoglycemia extremely low when used alone.
Weight Management: Breakthrough Weight Loss Data
If lowering blood sugar is the "basic skill" of Tirzepatide, then weight loss is the truly remarkable "killer feature" of this drug.
Global Data: The extent of weight loss is unprecedented
In the SURMOUNT-1 global Phase III trial that included 2,539 non-diabetic obese or overweight adults:
The 15mg dose group had an average weight reduction of 20.9% (approximately 22.5 kg) at 72 weeks, marking the first time in a Phase III clinical trial that a drug has achieved an average weight loss exceeding the 20% threshold.
The 10mg dose group achieved an average weight loss of 19.5%, and the 5mg group also showed significant results.
85% to 91% of the subjects achieved a weight reduction of ≥5% at 72 weeks, while the placebo group achieved only 35% (P < 0.001).
In the 15mg group, 63% of the subjects experienced a weight reduction of at least 20%, a proportion that is exceptional among all published clinical trials of weight loss drugs.
Chinese population data: equally outstanding
The SURMOUNT-CN study, published in JAMA in 2024, was led by the team of Professor Li Xiaoying from Zhongshan Hospital of Fudan University and was conducted in 29 medical centers across China:
A total of 210 Chinese adults with a BMI of 28 kg/m² or higher, or a BMI of 24 kg/m² accompanied by at least one weight-related comorbidity were included.
At 52 weeks, the 15mg group achieved an average weight loss of 17.5% (16.1 kg), the 10mg group achieved an average weight loss of 13.6% (12.3 kg), and the placebo group only lost 2.1 kg.
85.8% (in the 15mg group) and 87.7% (in the 10mg group) of the participants achieved clinically significant weight loss of ≥5%.
61.4% (in the 15mg group) of the participants lost ≥15% of their weight, far exceeding that of the placebo group.
These data strongly demonstrate that the weight loss effect of Tirzepatide in the Chinese population is highly consistent with global data, and is not an accidental phenomenon specific to a certain group.
Body composition remodeling: Not just "losing weight"
The weight loss achieved with tirzepatide is not merely a loss of water weight, but rather a real reduction in fat and an improvement in body composition.
The total fat content decreased by an average of 33.9%, while the placebo group only decreased by 8.2%. The estimated treatment difference was -25.7 percentage points (95% CI, -31.4 to -20.0).
The ratio of total fat content to total lean meat content decreased from 0.93 at baseline to 0.70 (15mg group), indicating that muscle mass was well preserved during the weight loss process.
Waist circumference significantly decreased: In the SURMOUNT-CN study, the 15mg group had an average reduction of 14.5 cm in waist circumference, the 10mg group had a reduction of 11.4 cm, and the placebo group had only 2.6 cm. Waist circumference is an intuitive indicator of visceral fat, and this data indicates a significant reduction in visceral fat.
The level of adiponectin, a fat factor, increased: The study showed that Tirzepatide could increase adiponectin levels by up to 26% (10mg dose, 26 weeks). This fat factor participates in the dual regulation of glucose and lipid metabolism, and its increase has profound significance for metabolic health.
Multidimensional benefits of cardiovascular and metabolic health
The efficacy of tirzepatide extends beyond blood sugar and weight; it also shows a comprehensive improvement trend in cardiovascular and metabolic indicators.
Blood pressure improvement
In the post-analysis of the SUMMIT trial, the estimated reduction in blood volume in the Tirzepatide group was significantly associated with decreased blood pressure, reduced microalbuminuria, and increased 6-minute walking distance.
Optimization of lipid profile
The SURMOUNT-CN study showed that fasting insulin, very low-density lipoprotein cholesterol (VLDL-C), and triglycerides were significantly improved compared to the placebo group.
Blood glucose and insulin sensitivity
In patients with type 2 diabetes (SURMOUNT-2 study), at 72 weeks, the 15mg group showed a significant reduction in HbA1c, and the proportion of subjects requiring two or more antidiabetic drugs decreased from 38% to 32%, indicating that the medication burden for some patients was actually reduced.
Synergistic effect of combined insulin
In the SURPASS-5 and SURPASS-6 trials, Tirzepatide combined with basal insulin (insulin glargine or lispro insulin) improved HbA1c while reducing hyperglycemic and hypoglycemic events, demonstrating the advantages of comprehensive management through multi-mechanism combination.
Why is "dual-targeting" more powerful than "single-targeting"?
To understand the efficacy of Tirzepatide, one must return to its unique pharmacological design.
The supplementary role of the GIP pathway: Preclinical studies have confirmed that GIP can reduce food intake and increase energy expenditure. When combined with the action of GLP-1 receptor agonists, the effects on blood glucose levels and body weight are greater than those achieved by either pathway being activated alone.
Central appetite regulation: The once-weekly subcutaneous injection of an ultra-long-acting dual receptor agonist can reach the central nervous system (CNS) and peripheral adipose tissue. The additional GIP receptor agonism makes the feeling of fullness more pronounced, which is something that endogenous GIP cannot achieve due to its short half-life.
Biased signaling: At the GLP-1 receptor, Tirzepatide prefers cAMP generation rather than β-arrestin recruitment. This "biased agonism" is believed to further enhance insulin secretion efficiency.
In short, tirzepatide is not simply the combination of two drugs; rather, a single molecule simultaneously activates two metabolic pathways, producing a synergistic effect where "1+1>2."
Tirzepatide, with its unique dual GIP/GLP-1 receptor agonist mechanism, has delivered convincing clinical results across four key dimensions: glycemic control, weight management, body composition remodeling, and cardiovascular metabolic improvement. From a 2.24% reduction in HbA1c to an average weight loss of over 20%, from a 33.9% reduction in fat mass to a 26% increase in adiponectin, each piece of data points to the same conclusion: This is a truly multi-target, multi-benefit metabolic drug. It represents one of the most significant breakthroughs in the field of enteroinsulin in the past decade and has opened up a new path for the comprehensive management of type 2 diabetes and obesity.
